CPX-351

CPX-351 (Vyxeos) is a liposomal formulation co-encapsulating cytarabine and daunorubicin, designed for synergistic antitumor activity. It is widely used in acute myeloid leukemia (AML) research, with applications in both in vitro cytotoxicity assays and in vivo xenograft model studies to evaluate its efficacy and mechanism of action.

Product Specifications

CAS Number

1256639-86-7

Product Name Alternative

CPX351, CPX-351, CPX 351, Daunonubicin/cytarabine, Cytarabine/daunonubicin, Vyxeos

Purity

98.95% (May vary between batches)

Smiles

O[C@@H]1[C@@H] (O[C@H] (CO) [C@H]1O) N2C (=O) N=C (N) C=C2.OC=1C2=C ([C@@H] (O[C@H]3C[C@H] (N) [C@H] (O) [C@H] (C) O3) C[C@@] (C (C) =O) (O) C2) C (O) =C4C1C (=O) C=5C (C4=O) =C (OC) C=CC5